IMV Inc. · OTC:IMVIF
IMV — Immunovaccine — Investor Presentation (October 2013)
25 slides from IMV's investor presentation, October 2013
Slide 1: Immunovaccine Inc.
October 2013 Immunovaccine Inc. (TSX-V: IMV) Developing Cancer Immunotherapies and infectious disease vaccines Awarded 2012 Best Early Stage Biotechnology Company
Slide 2: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS This document contains forward-looking information pursuant to applicable securities law. All information that addresses activities or developments that we expect to occur in the future are forward-looking statements. Forward-looking statements are based on the estimates a
Slide 3: Market Opportunities for DepoVax Based Therapies and Vaccines
MARKET OPPORTUNITIES FOR DEPOVAX ™ BASED THERAPIES AND VACCINES • Cancer immunotherapies including vaccines: – To become treatment of choice for up to 60% of cancers – To exceed $35 billion/ year in the next decade • The vaccine market for infectious diseases was estimated at nearly $19 billion in 2
Slide 4: Immunovaccine Inc.
IMMUNOVACCINE INC. • Clinical stage biotechnology company based in Canada • Ongoing programs in multiple cancer and infectious disease indications • Publicly listed (TSXV: IMV) • 21 employees with scientific capabilities in: – Preclinical immunology – Analytical chemistry – Formulation research • Cu
Slide 5: Immunovaccine's Pipeline: Products Based on the DepoVax Platform
IMMUNOVACCINE’S PIPELINE PRODUCTS BASED ON THE DEPOVAX™ PLATFORM 5
Slide 6: DepoVax - An Immune Stimulating Platform
DEPOVAX™ - AN IMMUNE STIMULATING PLATFORM ENABLING STRONG T CELL AND ANTIBODY RESPONSES Producing sustained T cells and/ or rapid response antibodies Encapsulate in a Liposome then Lyophilize Antigen + Adjuvant Suspend in Oil • Targeted and enhanced • Holds and presents antigen + adjuvant immune res
Slide 7: Mechanism of Action for DepoVax - Creating a Strong Depot Effect
MECHANISM OF ACTION FOR DEPOVAX- CREATING A STRONG “DEPOT” EFFECT Prolonged presentation of vaccine components to enable strong immunity Immune cells DepoVaxTM- based deposit Histology of subcutaneous injection site in mouse Controlling vaccine processing by the immune system 7
Slide 8: Intellectual Property
INTELLECTUAL PROPERTY • 6 patent families (41 patents) in 11 jurisdictions for the DepoVax platform – Any antigen, any adjuvant, any indication – Issued patent providing international protection through 2021 – Pending patents extend protection to 2028, 2031and 2033 • A portfolio of patents to protec
Slide 9: Cancer Immunotherapy Opportunity DPX-Survivac
CANCER IMMUNOTHERAPY OPPORTUNITY DPX-SURVIVAC 9
Slide 10: Next-Next Generation Immunotherapies - Combining Monoclonal Antibody T Cell Therapy
“NEXT-NEXT” GENERATION IMMUNOTHERAPIES- COMBINING MONOCLONAL ANTIBODY T CELL THERAPY WITH ANTIGEN DIRECTED T CELL ACTIVATION Company Announcement Janssen (Johnson & October 3, 2013: Research and option agreement with DCPrime BV Johnson) to develop novel dendritic cell-based cancer vaccines Roche Oct
Slide 11: DPX-Survivac Opportunity
DPX-SURVIVAC OPPORTUNITY • A T cell activator immunotherapy targeting the broadly expressed tumor and cancer stem cell associated antigen Survivin • Enabled by the DepoVaxTM adjuvanting platform to produce strong and sustained T cell responses targeting micro-metastases and circulating tumor cells •
Slide 12: High Levels of Sustained CD8 T Cells Induced by DPX-Survivac in Ovarian Cancer
HIGH LEVELS OF SUSTAINED CD8 T CELLS INDUCED BY DPX-SURVIVAC THERAPY IN OVARIAN CANCER PATIENTS Low dose vaccine (0.1 mL) High dose vaccine (0.5mL) 4096 4096 2048 2048 SFU per 106 PBMCs 1024 1024 512 512 256 256 128 02-04 128 64 09-05 64 03-06 09-08 32 32 03-07 10-09 16 16 11-10 02-11 8 8 01-12 01-1
Slide 13: Survivin Specific CD8+ T Cells Detected Ex Vivo
SURVIVIN SPECIFIC CD8+ T CELLS DETECTED EX VIVO - EXAMPLE: SUBJECT 11-10 (HLA-A2+, HLA-A3+) SD0 SD21 SD42 SD70 SD126 A2 multimer 0.004 0.006 0.009 0.076 Ex vivo Not determined 0.183 4.22 2.42 7.16 7.74 In vitro Stim. A3 multimer 0.006 0.085 0.043 0.199 Ex vivo Not determined 0.064 22.4 4.25 8.24 4.4
Slide 14: DPX-Survivac Therapy Induces Important CD4+ and CD8+ T Cell Phenotypes
DPX-SURVIVAC THERAPY INDUCES SEVERAL IMPORTANT CD4+ AND CD8+ T CELL PHENOTYPES IN CANCER PATIENTS "Total" IFNg Cohort C Mean values of all cohort C patients + 1.00 CD4EMEffector Memory CD4+ (% of CD4+ or CD8+ Phenotype) 0.90 + CD8CM CD8+ Central Memory 0.80 + 0.70 CD8EM CD8+ Effector Memory + 0.35 C
Slide 15: DPX-Survivac Induces Sustained Poly-Functional T Cells Dose Dependently
DPX-SURVIVAC THERAPY INDUCES SUSTAINED POLY- FUNCTIONAL T CELLS IN A DOSE DEPENDANT MANNER Cohort B (0.1 mL+ cyclophosphamide) Cohort C (0.5 mL+ cyclophosphamide) SD0 SD21 SD42 SD70 SD126 SD0 SD21 SD42 SD70 SD126 CD4+ EM CD8+ CM CD8+ EM CD8+ LD IFNg / TNF / IL2 IL2 / TNFa IFNg / IL2 IL2 IFNg / TNFa
Slide 16: Positive Trend for Delayed Progression in Patients Responding to DPX-Survivac
POSITIVE TREND FOR DELAYED PROGRESSION IN PATIENTS RESPONDING TO DPX-SURVIVAC Time to Progression (n=18) 1 Proportion of Progression-Free Patients 0.9 0.8 0.7 0.6 0.5 Strong Responders 0.4 Low and Negative Responders 0.3 0.2 0.1 0 0 100 200 300 400 500 Time (Days) The two groups are balanced immunol
Slide 17: DPX-Survivac Clinical Development
DPX-SURVIVAC CLINICAL DEVELOPMENT • Canada’s NCIC Clinical Trials Group (NCIC-CTG) to sponsor and conduct a large randomized controlled phase 2 study – Trial in 250 patients with advanced ovarian cancer to be initiated in 1H2014 – Designed to assess progression free survival in combination with cycl
Slide 18: Infectious Disease and Bioterrorism Applications
INFECTIOUS DISEASE AND BIOTERRORISM APPLICATIONS 18
Slide 19: Infectious Disease and Bioterrorism Vaccines
INFECTIOUS DISEASE AND BIOTERRORISM VACCINES • RSV vaccine for the elderly – Targeting a new RSV antigen with a novel mechanism of action – Entering a fully funded phase 1 study in 2014 • Anthrax vaccine for civilian and military use – Rapid response potential demonstrated in NIH-led studies – Estab
Slide 20: IMV and Profile of Select NASDAQ Listed Companies
IMV AND PROFILE OF SELECT NASDAQ LISTED COMPANIES
Slide 21: Publicly Traded Biotech Companies with Cancer Vaccine Programs
PUBLICLY TRADED BIOTECH COMPANIES WITH CANCER VACCINE PROGRAMS Company Market Cap ($M) Vaccines Indication (Phase) Oct 4, 2013 Immunovaccine 25.3 DPX-Survivac, Ovarian (Phase 1-2) TSXV: IMV DPX-0907 GBM (Phase 1-2) Galena Biopharma, Inc 193.35 Nelipepimut-s (NeuVax) Breast Cancer (Phase 3) NASDAQ:GA
Slide 22: Recent Transactions of Companies Targeting Cancer Stem Cells
RECENT TRANSACTIONS OF COMPANIES TARGETING CANCER STEM CELLS Company Market cap Class of drug Applicable Cancer(s) Stage of Recent (10/4/13) Development Transaction Verastem, Inc. 298.17 Mesothelioma, July 22, 2013- (NASDAQ: Small molecule Ovarian, NSCLC, solid Phase 2 US$63.8 Million VSTM) and hema
Slide 23: Immunovaccine Goals
IMMUNOVACCINE GOALS Capitalize on the potential of DepoVax™ in cancer immunotherapy Diversify by pursuing select applications and licensing opportunities Rapidly advance a sophisticated clinical pipeline Transform into a mid-stage clinical development company 23
Slide 24: Strong Leadership and Experience: Management & Board
STRONG LEADERSHIP AND EXPERIENCE MANAGEMENT & BOARD Management • Albert Scardino, Executive Chairman • Marc Mansour, Ph.D., Chief Operating Officer • Kimberly Stephens, CA, Chief Financial Officer • Vicki Morgan, MBA, VP, Business Development Board Members • Wade K. Dawe CEO of Brigus Gold (NYSE Ame
Slide 25: Immunovaccine Inc. (TSX-V: IMV)
IMMUNOVACCINE INC. (TSX-V: IMV) For more information: Marc Mansour, PhD Chief Operating Officer T: 902-492-1819 E: mmansour@imvaccine.com www.imvaccine.com